Jiangsu HengRui registers Phase 3 trial of SHR-3167 vs insulin glargine
The study plans to enroll 450 insulin-naive type 2 diabetes participants to compare once-weekly SHR-3167 with once-daily insulin glargine. It is planned to start in November 2026 and complete primary outcomes in October 2027.
Primary source
ClinicalTrials.gov registry record, November 6, 2026
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Read the source: Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation